During the last session, TherapeuticsMD Inc. (NASDAQ:TXMD)’s traded shares were 1.21 million, with the beta value of the company hitting 2.10. At the end of the trading day, the stock’s price was $2.98, reflecting an intraday loss of -13.87% or -$0.48. The 52-week high for the TXMD share is $69.50, that puts it down -2232.21 from that peak though still a striking -15.77% loss since the share price plummeted to a 52-week low of $3.45. The company’s market capitalization is $1.46B, and the average intraday trading volume over the past 10 days was 0.64 million shares, and the average trade volume was 214.52K shares over the past three months.
TherapeuticsMD Inc. (TXMD) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.00. TXMD has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight.
TherapeuticsMD Inc. (NASDAQ:TXMD) trade information
TherapeuticsMD Inc. (TXMD) registered a -13.87% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -13.87% in intraday trading to $2.98 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -65.49%, and it has moved by -79.82% in 30 days. Based on these gigs, the overall price performance for the year is -94.38%. The short interest in TherapeuticsMD Inc. (NASDAQ:TXMD) is 22.76 million shares and it means that shorts have 2.92 day(s) to cover.
The consensus price target of analysts on Wall Street is $87.50, which implies an increase of 96.59% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $50.00 and $125.00 respectively. As a result, TXMD is trading at a discount of -4094.63% off the target high and -1577.85% off the low.
TherapeuticsMD Inc. (TXMD) estimates and forecasts
Statistics show that TherapeuticsMD Inc. has underperformed its competitors in share price, compared to the industry in which it operates. TherapeuticsMD Inc. (TXMD) shares have gone down -91.68% during the last six months, with a year-to-date growth rate less than the industry average at -54.76% against 9.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.10%. While earnings are projected to return 34.90% in 2022, the next five years will return 17.60% per annum.
TherapeuticsMD Inc. is due to release its next quarterly earnings between February 28 and March 04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TherapeuticsMD Inc. (NASDAQ:TXMD)’s Major holders
TherapeuticsMD Inc. insiders own 6.95% of total outstanding shares while institutional holders control 35.09%, with the float percentage being 37.72%. Blackrock Inc. is the largest shareholder of the company, while 183 institutions own stock in it. As of Dec 30, 2021, the company held over 24.89 million shares (or 5.87% of all shares), a total value of $8.85 million in shares.
The next largest institutional holding, with 18.91 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 4.46% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $14.02 million.
Also, the Mutual Funds coming in first place with the largest holdings of TherapeuticsMD Inc. (TXMD) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Sep 29, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 9.83 million shares. This amounts to just over 2.32 percent of the company’s overall shares, with a $7.29 million market value. The same data shows that the other fund manager holds slightly less at 9.07 million, or about 2.14% of the stock, which is worth about $4.49 million.